{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:42:58Z","timestamp":1764603778204,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ijid.2021.07.015","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T12:33:35Z","timestamp":1626266015000},"page":"261-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19"],"prefix":"10.1016","volume":"109","author":[{"given":"Tomoyuki","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshie","family":"Shinagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanobu","family":"Kobata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemitsu","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.07.015_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.07.020","article-title":"Distinct early serological signatures track with SARS-CoV-2 survival","volume":"53","author":"Atyeo","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ijid.2021.07.015_bib0002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41586-020-2772-0","article-title":"Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion","volume":"588","author":"Benton","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2021.07.015_bib0003","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijid.2021.07.015_bib0004","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jinf.2013.03.015","article-title":"Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests","volume":"67","author":"Chan","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2021.07.015_bib0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijid.2021.07.015_bib0006","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41591-020-1083-1","article-title":"Seasonal coronavirus protective immunity is short-lasting","volume":"26","author":"Edridge","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2021.07.015_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238089","article-title":"Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma","volume":"15","author":"Farrera-Soler","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2021.07.015_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2021.07.015_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2021.07.015_bib0010","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ijid.2021.07.015_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.011","article-title":"A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies","volume":"182","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2021.07.015_bib0012","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19 \u2013 preliminary report","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2021.07.015_bib0013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2021.07.015_bib0014","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jcv.2018.01.019","article-title":"Human coronavirus circulation in the United States 2014\u20132017","volume":"101","author":"Killerby","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ijid.2021.07.015_bib0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2021.07.015_bib0016","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ijid.2021.07.015_bib0017","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2021.07.015_bib0018","doi-asserted-by":"crossref","first-page":"7411","DOI":"10.1128\/JVI.00079-09","article-title":"Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide","volume":"83","author":"Madu","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.ijid.2021.07.015_bib0019","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijid.2021.07.015_bib0020","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1093\/infdis\/jir084","article-title":"Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model","volume":"203","author":"Miyoshi-Akiyama","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2021.07.015_bib0021","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijid.2021.07.015_bib0022","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41467-020-16638-2","article-title":"Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients","volume":"11","author":"Poh","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2021.07.015_bib0023","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1172\/JCI142804","article-title":"COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain","volume":"130","author":"Secchi","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijid.2021.07.015_bib0024","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2021.07.015_bib0025","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4250","article-title":"Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity","volume":"370","author":"Shrock","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijid.2021.07.015_bib0026","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/22221751.2020.1762515","article-title":"Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients","volume":"9","author":"Sun","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijid.2021.07.015_bib0027","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1021\/acscentsci.0c00742","article-title":"SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution","volume":"6","author":"Wang","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.ijid.2021.07.015_bib0028","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2021.07.015_bib0029","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41590-020-00814-z","article-title":"Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19","volume":"21","author":"Woodruff","year":"2020","journal-title":"Nat Immunol"},{"year":"2021","series-title":"World Health Organization coronavirus dashboard","key":"10.1016\/j.ijid.2021.07.015_bib0030"},{"key":"10.1016\/j.ijid.2021.07.015_bib0031","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1080\/22221751.2020.1815591","article-title":"Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population","volume":"9","author":"Yi","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijid.2021.07.015_bib0032","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221005713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221005713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:59:22Z","timestamp":1761119962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221005713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":32,"alternative-id":["S1201971221005713"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.07.015","relation":{},"ISSN":["1201-9712"],"issn-type":[{"type":"print","value":"1201-9712"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}